My Financial News from United States, Investment

from Bing and Google News
United States , Thursday 16 April 2026

Cabaletta Bio (NASDAQ:CABA) Upgraded by Zacks Investment Research to Buy

Published on: Wednesday 25 May 2022

Cabaletta Bio (NASDAQ:CABA) Upgraded by Zacks Investment Research to Buy Cabaletta Bio (NASDAQ:CABA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The firm presently has a $1.50 target price on the stock. Zacks Investment Research‘s price target points to a potential upside of […]


News source: https://www.defenseworld.net/2022/05/25/cabaletta-bio-nasdaqcaba-upgraded-by-zacks-investment-research-to-buy.html

Share this news on:  

RELATED NEWS

» Short Interest in MFS Investment Grade Municipal Trust (NYSE:CXH) Drops By 92.0%
» VENTURE GLOBAL ANNOUNCES FINAL INVESTMENT DECISION AND FINANCIAL CLOSE FOR PLAQUEMINES LNG
» Cabaletta Bio (NASDAQ:CABA) Upgraded by Zacks Investment Research to Buy
» Blue Lagoon Completes $5.7 Million Private Placement Lead by a Second Strategic Investment by Crescat Capital
» CFA Institute Announces Signatory Organizations to New Diversity, Equity, and Inclusion Code for the Investment Profession in US and Canada

HEADLINE NEWS